FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare

SPOTLIGHT: New data on Actemra


Roche's RA drug Actemra showed equal efficacy rates when compared with other anti-TNF therapies in a late-stage trial, according to researchers. About 58 percent of the patients taking the drug had a 20 percent improvement in their condition, a significant drop from the 74 percent of patients who marked similar progress in a mid-stage trial. Report

Comments

Does anyone know when Actemra will be FDA approved and available to patients outside those in the clinical trials?

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 50 + 11?
To combat spam, please solve the math question above.